Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study

The objective of this study was to investigate the efficacy and safety of adjunctive lanicemine (NMDA channel blocker) in the treatment of major depressive disorder (MDD) over 12 weeks. This phase IIb, randomized, parallel-arm, double-blind, placebo-controlled study was conducted at 49 centers in fo...

Full description

Saved in:
Bibliographic Details
Published in:Neuropsychopharmacology
Main Authors: Sanacora, Gerard, Johnson, Michael R, Khan, Arif, Atkinson, Sarah D, Riesenberg, Robert R, Schronen, Juan P, Burke, Michael A, Zajecka, John M, Barra, Luis, Su, Hong-Lin, Posener, Joel A, Bui, Khanh H, Quirk, Michael C, Piser, Timothy M, Mathew, Sanjay J, Pathak, Sanjeev
Format: Artigo
Language:Inglês
Published: Nature Publishing Group 2017
Subjects:
Original Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5312066/
https://ncbi.nlm.nih.gov/pubmed/27681442
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/npp.2016.224
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items